China's Second-largest CRO Seeks Initial Public Offering In The U.S.
This article was originally published in PharmAsia News
Seeking to join top competitor WuXi PharmaTech on the New York Stock Exchange, ShangPharma, the second-largest contract research organization in China, is looking to raise an estimated $89.9 million in an initial public offering expected to debut the week of Oct. 18
You may also be interested in...
ShangPharma Biologics Head Mitchell Reff On Biologics R&D In China: An Interview With PharmAsia News
ShangPharma’s new Chief Biologic Officer Mitchell Reff discusses the company’s expansion into biologics and his views on biologics development in China.
Will WuXi Benefit From Rival ShangPharma Going Private?
China’s second largest CRO ShangPharma is likely to go private after a proposal from its founder, and some say the exit may also help its larger rival WuXi PharmaTech.
Chinese CRO ShangPharma Opens New Facility To Support Lilly's Pipeline
China’s second-largest CRO opens new Shanghai facility to support its largest client.